Search Results: (30 results)

This study tests whether COM701 (an anti‑PVRIG immunotherapy) given every 3 weeks as maintenance can delay cancer growth after a good response to platinum chemotherapy. Adults with relapsed platinum‑sensitive ovarian, fallopian tube, or primary peritoneal cancer are randomized 2:1 to COM701 or placebo.

This phase II study is testing low-dose tamoxifen, with or without high-dose omega-3 fatty acids, in postmenopausal women who are overweight or obese and at increased risk for breast cancer.

The purpose of this study is to understand knowledge and opinions about pancreatic cancer screening, access to and decision-making around screening, and how a blood-based test might influence screening among individuals with inherited (germline) mutations associated with increased pancreatic cancer risk, including APC, ATM, BRCA1, BRCA2, CDKN2A, EPCAM, MLH1, MSH2, MSH6, PALB2, PMS2, STK11, and TP53. 

The Vanguard Study is looking at how multi-cancer detection (MCD) blood tests could fit into cancer screening.

This is a Phase III, randomized, global, open-label clinical trial to see if a new drug Daraxorasib (RMC-6236) helps prevent pancreatic cancer from returning after surgery and chemotherapy.

This study is looking at how well an experimental blood test works for finding possible cancers earlier in people who have a higher-than-average risk of cancer because of an inherited mutation.

We are conducting a fully-online research study to learn more about how genes affect your risk of breast cancer. No office visit is required. Participants provide consent online, answer questions online about their health and medical history, and provide DNA via a saliva sample using a pre-paid mailer through the mail. In return for participation, study participants may receive information about their genetic ancestry for free.

This observational study follows participants over time to better understand the long-term effects of nipple-sparing mastectomy.

This trial will study the safety, tolerability, and initial effectiveness of MOMA-341, a new type of targeted therapy, alone or in combination with a standard chemotherapy (irinotecan) or together with an immunotherapy to treat people with advanced or metastatic cancers with certain types of mutations.

This study is testing whether taking daraxonrasib, a new oral cancer medicine, after surgery and standard chemotherapy can help people with pancreatic cancer stay cancer-free for longer.

This study is testing two different vaccine-based treatment approaches combined with immunotherapy for people with pancreatic cancer that can be removed with surgery

This trial will study the safety, tolerability, and initial effectiveness of MOMA-313, a new type of targeted therapy, alone or in combination with the PARP inhibitor olaparib to treat people with advanced or metastatic cancers with certain types of mutations.

This clinical trial is testing whether two targeted cancer drugs taken together work better than one drug alone for treating advanced endometrial cancer that has come back or did not respond to prior treatment. To be eligible, the cancer must test positive for a biomarker known as a RAS pathway mutation.

Researchers are conducting a study to better understand how people make important health decisions and how they feel about those decisions over time. The goal of this study is to learn what factors help patients feel confident and satisfied with their health-related decisions, as well as what may lead to regret or uncertainty later on.

This research study is enrolling prostate cancer patients who plan to undergo surgery to have their prostate removed (radical prostatectomy) and whose cancer has one of the listed gene mutations: ATM, BRCA1, BRCA2, CHEK2, PALB2, RAD51B, RAD51C, RAD51D, RAD54L2, BARD1, FANCA or BRIP1.

This study is testing an experimental vaccine that helps the immune system recognize changes in a protein called KRAS, which is commonly involved in pancreatic cancer. The vaccine is given with an immune-boosting medicine that helps improve the body’s response.

This study is testing whether a new targeted therapy called AZD5335 works better than currently used treatments for people with platinum‑resistant ovarian, fallopian tube, or primary peritoneal cancer.The study is looking at how long people live without their cancer getting worse while taking AZD5335 compared with standard treatments. 

This study is testing whether a type of blood test called a liquid biopsy can find very small amounts of cancer left in the body after treatment—before cancer shows up on scans or causes symptoms.The blood test looks for circulating tumor DNA (ctDNA), tiny pieces of cancer DNA that may be present in the bloodstream. Researchers want to learn how well this test can:

• Detect cancer recurrence early
• Predict outcomes after treatment
• Support future use of blood‑based monitoring instead of—or in addition to—imaging tests

CAR-T therapy is a type of immunotherapy that uses the patient's own immune cells in order to treat their cancer. With CAR-T therapy, the immune cells are removed from the blood and enhanced in the lab to improve their ability to kill cancer cells. The goal of this clinical trial is to learn the safety and effectiveness of an experimental CAR-T combination known as CLBR001+ABBV-461 for treating people with metastatic breast cancer. Another goal is to learn the best dose of this combination for treating metastatic breast cancer. 

This study collects health information and DNA samples such as blood or saliva from participants to help researchers better understand cancer risk and early detection.

The FourLight-3 clinical trial compares a study treatment, atrimociclib combined with letrozole, against standard approved treatments. The clinical trial is for adults with advanced or metastatic HR-positive, HER2-negative breast cancer who have not received prior treatment for advanced/metastatic disease. 

Genetic risk screening and genetic testing study for Black/African American adults ages 18 and older in the Houston, Texas area.

This study is testing whether a new targeted drug called puxitatug samrotecan (Puxi-Sam) works better than standard chemotherapy for treating advanced or metastatic endometrial cancer whose cancer has grown or returned after prior treatment with platinum chemotherapy and immunotherapy. 

Anonymous online survey enrolling adults with cancer who have met with a surgeon about possible cancer surgery

This study is testing palazestrant (also called OP-1250), an investigational medicine, for people with estrogen receptor-positive (ER-positive), HER2-negative advanced or metastatic breast cancer.

Study to understand how people with inherited CDH1 or CTNNA1 mutations perceive their risk of gastric (stomach) cancer and their attitudes toward endoscopic surveillance and other medical options.

This study is testing a new treatment that combines a KRAS-targeted cancer vaccine (ELI-002) with two immunotherapy drugs (balstilimab and botensilimab) in people with advanced colorectal or pancreatic cancers with a KRAS tumor mutation and a marker known as mismatch repair proficiency (pMMR or MMR-p).

This is a Phase 2 treatment trial enrolling adults with advanced pancreatic cancer or advanced non-small cell lung cancer that has continued to grow despite standard immunotherapy.

This study explores how medical stress affects families with genetic conditions and their relationships with healthcare providers to improve future support.

Survey to identify potential determinants impacting time from symptom onset to ovarian cancer diagnosis